89bio, Inc.
ETNB
$9.37
-$0.22-2.29%
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 7.61M | 7.93M | 7.21M | 6.22M | 6.30M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 41.21M | 39.35M | 42.13M | 28.52M | 25.36M |
Operating Income | -41.21M | -39.35M | -42.13M | -28.52M | -25.36M |
Income Before Tax | -36.37M | -34.73M | -38.39M | -28.84M | -24.59M |
Income Tax Expenses | 3.87M | -- | -- | -- | 16.00K |
Earnings from Continuing Operations | -40.24M | -34.73M | -38.39M | -28.84M | -24.60M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -40.24M | -34.73M | -38.39M | -28.84M | -24.60M |
EBIT | -41.21M | -39.35M | -42.13M | -28.52M | -25.36M |
EBITDA | -41.19M | -39.34M | -42.12M | -28.51M | -25.35M |
EPS Basic | -0.50 | -0.45 | -0.52 | -0.54 | -0.48 |
Normalized Basic EPS | -0.30 | -0.28 | -0.32 | -0.35 | -0.31 |
EPS Diluted | -0.50 | -0.45 | -0.52 | -0.54 | -0.48 |
Normalized Diluted EPS | -0.30 | -0.28 | -0.32 | -0.35 | -0.31 |
Average Basic Shares Outstanding | 80.70M | 76.34M | 74.13M | 53.17M | 50.81M |
Average Diluted Shares Outstanding | 80.70M | 76.34M | 74.13M | 53.17M | 50.81M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |